Chris Campbell is the Chair of DLA Piper's Product Liability and Mass Tort practice group, which is among the world's largest and most award-winning team of product liability defense counsel. Chris regularly speaks and writes on the topics of product liability, mass torts, and class action litigation, as well as the attorney-client privilege, expert witnesses, pharmacovigilance, trial tactics, and other topics.
Tony Sadek is a pharmacist and associate in DLA Piper’s Product Liability, Mass Tort, and Product Stewardship group. He focuses his practice on pharmaceutical and medical device litigation, mass torts, product liability, and regulatory issues. Prior to joining DLA Piper, Tony worked at an expert witness company, connecting law firms to experts who meet their case needs.
Live Video-Broadcast: June 18, 2025
Sign-up for a law firm subscription plan and each attorney in the firm receives free access to all CLE Programs
This program provides a comprehensive guide to defending mass tort litigations, covering both fundamental principles and advanced strategies. Attendees will gain insights into managing federal multidistrict litigations (MDLs), state-coordinated proceedings, and global mass torts. Key topics include drafting effective pleadings, structuring discoveries to ensure balanced disclosures, identifying and addressing critical legal and expert issues early, and developing strategic approaches to bellwether case selection and trial. The session will also explore best practices for coordinating defense efforts across multiple jurisdictions.
This course is co-sponsored with myLawCLE.
Key topics to be discussed:
Date / Time: June 18, 2025
Closed-captioning available
Christopher G. Campbell | DLA Piper LLP
Chris Campbell is the Chair of DLA Piper’s Product Liability and Mass Tort practice group, which is among the world’s largest and most award-winning team of product liability defense counsel. A graduate of Harvard Law School, Chris has 20 years’ experience in all phases of mass tort, class action, and other complex commercial litigation, including trying cases and arguing appeals. He has served as global, national, and trial counsel for many global companies in the life sciences, food and beverage, automotive, and insurance sectors. In addition, Chris also advises clients on regulatory, communications, and other strategic matters with the potential to impact the clients’ business interests or reputations.
Clients say of Chris: “He is great. Period.” Others praise the quality of his strategic advice and devotion to client service as “truly indispensable” to their teams, noting their gratitude for “all the help (almost around the clock!) and good advice.” The Legal 500 United States has repeatedly recognized Chris, noting that he “commands respect.” Law360 selected Chris as a “Rising Star” in the area of product liability, citing his “knack for breaking down difficult science into concepts” and “creativity and unorthodox tactics” that “have set him apart.”
Chris regularly speaks and writes on the topics of product liability, mass torts, and class action litigation, as well as the attorney-client privilege, expert witnesses, pharmacovigilance, trial tactics, and other topics.
Antonious E. Sadek, PharmD. | DLA Piper
Tony Sadek is a pharmacist and associate in DLA Piper’s Product Liability, Mass Tort, and Product Stewardship group. He focuses his practice on pharmaceutical and medical device litigation, mass torts, product liability, and regulatory issues. As a pharmacist, Tony served as pharmacy practicing consulting to clients. After law school, Tony clerked for mass tort judges at both the federal and state level. Prior to joining DLA Piper, Tony worked at an expert witness company, connecting law firms to experts who meet their case needs.
I. Defining and narrowing mass tort claims at the pleading stage | 1:00pm – 1:30pm
II. Designing affirmative discovery to balance the disclosure obligations on both sides | 1:30pm – 2:00pm
Break | 2:00pm – 2:10pm
III. Identifying dispositive legal, expert, and other issues and getting them heard early | 2:10pm – 2:30pm
IV. Bellwether case selection and trial strategies | 2:30pm – 2:50pm
V. Federal, state, and global coordination | 2:50pm – 3:10pm
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Pending CLE Approval
2 General
Approved for CLE Credits
2 General
No MCLE Required
2 CLE Hour(s)
Pending CLE Approval
2 General
Approved via Attorney Submission
2.5 General Hours
Pending CLE Approval
2 General
Approved for CLE Credits
2.4 General
Pending CLE Approval
2 General
Pending CLE Approval
2 General
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Pending CLE Approval
2 Substantive
Pending CLE Approval
2 General
Pending CLE Approval
2 General
No MCLE Required
2 CLE Hour(s)
No MCLE Required
2 CLE Hour(s)
Pending CLE Approval
2 General
No MCLE Required
2 CLE Hour(s)
Pending CLE Approval
2 General
Approved for CLE Credits
2.4 General
Pending CLE Approval
2 General
Pending CLE Approval
2 General
Pending CLE Approval
2 General
Approved for CLE Credits
2 General
Pending CLE Approval
2 General
Approved for CLE Credits
120 General minutes
Approved for CLE Credits
2.4 General
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Approved for CLE Credits
2.4 General
Pending CLE Approval
2 General
Pending CLE Approval
2.5 General
Pending CLE Approval
2 General
Approved for CLE Credits
2 General
Pending CLE Approval
2.5 General
Pending CLE Approval
2 General
No MCLE Required
2 CLE Hour(s)
Approved for CLE Credits
2 General
Approved for CLE Credits
2 General
Pending CLE Approval
2 General
Not Eligible
2 General Hours
Approved for CLE Credits
2 General
Approved via Attorney Submission
2 Law & Legal Hours
Pending CLE Approval
2.4 General
Pending CLE Approval
2.4 General
Pending CLE Approval
2 General